Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies-Reference-Cited by-同舟云学术

Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies

Published:2019-11-20 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Khoury Tawfik,Ilan Yaron

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference143 articles.

1. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis;Taylor;Nat Rev Rheumatol.,2009

2. Optimizing anti-TNF treatment in inflammatory bowel disease;Rutgeerts;Gastroenterology.,2004

3. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population;Ha;Clin Gastroenterol Hepatol.,2012

4. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis;Finckh;Ann Rheum Dis.,2006

5. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment;Kalden;Nat Rev Rheumatol.,2017

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Low Adherence to Chronic Medications by Improving their Effectiveness using a Personalized Second-generation Digital System;Current Pharmaceutical Biotechnology;2024-12

2. Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial;Frontiers in Oncology;2024-07-30

3. Free Will as Defined by the Constrained Disorder Principle: a Restricted, Mandatory, Personalized, Regulated Process for Decision-Making;Integrative Psychological and Behavioral Science;2024-06-20

4. A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy;Journal of Clinical Medicine;2024-06-05

5. Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy;International Immunopharmacology;2024-06